



## Short stature

Rasha Odeh  
MB,BS.MRCPCH

Assistant professor of pediatric  
endocrinology  
University of Jordan




# Growth

- Growth in childhood, one of the most fascinating, complex and dynamic biological processes, is tightly controlled and regulated.
- remains one of the most useful of all indices of public health and economic well being, specifically in developing countries and countries in transition

# Growth Parameters

- Weight for age
- Height (length) for age
- Weight for length
- Body mass index for age
- Head circumference for age

overweight:  
BMI > 85<sup>th</sup> < 95<sup>th</sup>  
percentile  
Obese:  
BMI > 95<sup>th</sup>  
percentile






**Birth to 24 months: Girls**  
**Length-for-age and Weight-for-age percentiles**

NAME \_\_\_\_\_

RECORD # \_\_\_\_\_



Published by the Centers for Disease Control and Prevention, November 1, 2009  
 SOURCE: WHO Child Growth Standards (<http://www.who.int/childgrowth/en>)





# Outline

- Normal Growth and puberty
- Causes of short stature
- Approach to a short child



# The ICP concept of growth:


Infancy

Childhood

Puberty

A mathematical model breaking down linear growth from birth to adulthood into 3 components that reflect the different hormonal phases of the growth process.

# ICP Concept



# ICP Concept - Infantile Phase

- Rapid period of growth from 0 - 2 years
- Continuation of the rapid but decelerating intra-uterine growth phase
- Depends on factors such as nutrition, insulin and the insulin-like growth factors.
- Largely independent of growth hormone

# ICP Concept - Infantile Phase


- In general, birth size reflects intra-uterine environment, e.g. nutrition
- Birth size, therefore, has relatively poor correlation with final height.
- From birth to age 2, infant “tracks” on to his/her genetic centile, related to parental heights

# Girls

Head  
cm

Weight  
kg

Length  
cm



Reg. No. \_\_\_\_\_  
Surname \_\_\_\_\_  
Forename \_\_\_\_\_  
Date of Birth     /     /  
Expected Date of Delivery (EDD)     /     /

---

Treatment/Notes

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Key to Centiles	
-----	97th
-----	90th
-----	50th
-----	10th
-----	3rd

# ICP Concept - Childhood Phase

- Long phase of growth from 2 ~ 12 years (onset of pubertal growth)
- Slower, slightly decelerating curve
- Dependent on growth hormone & thyroxine
- Healthy child will stay on childhood (genetic) centile until puberty

# ICP Concept - Pubertal Phase

- From around age 12 (time of puberty) to final height
- Dependent on the sex steroid estrogen which is aromatised from testosterone and which causes an increase in growth hormone secretion
- Resulting growth acceleration is limited by fusion of the epiphyses (due to estrogen in both sexes)

# ICP Concept - Pubertal Phase

- Variable growth phase in terms of :  
*age of onset • duration • intensity*
  
- 95% of normal individuals will attain final heights within 2 standard deviations of mid-parental height ( $\pm 8.5$  cm)



# Pubertal (Tanner) staging



	Genitals Tanner stage			Pubic hair Tanner stage	
	Boys	Girls		Boys and girls	
Testes < 2.0 cm max. length			G1	No mammary tissue	P1 No pubic hair
Testes > 2.0 cm max. length			G2	Small nubbin mammary tissue behind areola	P2 Sparse growth, slightly pigmented downy hair at base of penis or along labia
Penis lengthening, testes increasing in size			G3	Distinct breast contour	P3 Sparse growth, darker, curled pubic hair at base of penis or along labia
Penis broadening, glans develops, testes increasing in size			G4	Double contour of breast	P4 Small adult configuration
Adult male genitals, testes average 5-6 cm max. length			G5	Single adult breast contour	P5 Adult configuration


# Stages of breast development versus height velocity in girls

B1 – prepubertal	Prepubertal (childhood phase)
B2 – breast budding	Increase in height velocity
B3 – breast mound	Peak height velocity B2-3
B4 – angle between areola and breast mound	Slowing of height velocity; onset of periods (menarche)
B5 – adult breast shape	Adult height

# Genital stages versus height velocity in boys

G1 – prepubertal scrotum and penis, testicular volume <4 ml	Prepubertal – childhood phase
G2 – prepubertal penis, enlargement of scrotum, testes $\geq 4$ ml	Still in childhood phase, therefore height velocity slower than in G1
G3 – penis begins to enlarge	Increase in height velocity
G4 – penis lengthens and broadens, testes ~12-15 ml	Peak height velocity
G5 – adult, testes ~ 15-20 ml	Significant further growth followed by final height

# Height velocity graph showing different growth patterns in boys (solid line) and girls (dotted line)




# Mid-parental height and target range - girls

- Plot Mother's height on growth chart
- Plot Father's height *minus 13* cm
- Plot the mid-parental height (MPH)  
(the mean of these two measurements)
- Plot the target range (MPH  $\pm$  8.5 cm)

# Mid-parental height and target range - boys

- Plot Father's height on growth chart
- Plot Mother's height *plus* 13 cm
- Plot the mid-parental height (MPH)  
(the mean of these two measurements)
- Plot the target range (MPH  $\pm$  8.5 cm)



# Essentials for growth assessment

- Reliable, accurate measuring equipment
- Accurate measurement of child & parents
- Calculation of decimal age and height velocity
- Careful plotting of growth chart
- Calculation of mid-parental height (MPH) and target range
- Pubertal staging
- Bone age assessment



# Measurement of Height

- Reliable, accurate measuring equipment
- Accurate measurement of child & parents !
- Frankfurt plane
- Stretched height
- Measurement of sitting height in selected cases



The 5th Congress of the Jordanian Society  
of Endocrinology, 11-14/5/2017

## Techniques of measurement Length




# Evaluation of Growth

- How short is the child?
- Is the child's height velocity (HV) impaired?
- What is the child's likely adult height?
- Is the child growing on a centile appropriate for the genetic target height?

Is the child short?




# Relationship between centiles and standard deviations for values with a Gaussian distribution



# Height-for-age BOYS


5 to 19 years (z-scores)





# Height-for-age BOYS


5 to 19 years (percentiles)



2007 WHO Reference

## 2 to 20 years: Boys Stature-for-age and Weight-for-age percentiles

NAME \_\_\_\_\_ RECORD # \_\_\_\_\_



Published May 30, 2000 (modified 11/21/00).  
SOURCE: Developed by the National Center for Health Statistics in collaboration with  
the National Center for Chronic Disease Prevention and Health Promotion (2000).  
<http://www.cdc.gov/growthcharts>




SAFER · HEALTHIER · PEOPLE™



# Short stature:


Height below 2 standard deviations from the mean. ( 3<sup>rd</sup> centile)



# Is the child's height velocity (HV) impaired?


## Growth failure:

- Failure to maintain a HV that is appropriate for age and maturity.
- HV should be calculated in ( cm/year) using accurate measurements of height and an interval between measurements of at least **six months**



# For children two years and older, **growth failure is likely** if:

- The height-for-age curve has deviated downwards across two major height percentile curves.
- Or, if the child is growing slower than :
  - Age 2-4 years: HV less than 5.5 cm/year
  - Age 4-6: HV less than 5 cm/year
  - Age 6 years to puberty:
    - HV less than 4 cm/year for boys
    - HV less than 4.5 cm/year for girls



# Failure to thrive/weight faltering:

Term usually applied to infants and pre-school children, denoting failure to gain weight at an appropriate rate

# What is the child's likely adult height?

- Many methods, different accuracies but in general it depends on:
  1. Mid parental height (target height)
  2. Bone age : Greulich & Pyle, Tanner Whitehouse...



# X-ray of left hand and wrist for bone age assessment




# Causes of Short Stature

- Normal (genetic and constitutional delay)
- Small for gestational age
- Dysmorphic syndromes
- Skeletal dysplasias
- Chronic disease
- Endocrine
- Dire social circumstances!
- Idiopathic short stature

# Normal genetic short stature


- Child short and normal
- Parent(s) short and normal
- Bone age not delayed
- Child destined to become short adult

## Familial (genetic) short stature



# Constitutional delay

- Child short, normal but looks younger than chronological age
- Parent(s) not short, but may have been so in childhood
- Bone age delayed
- Late puberty and catch-up growth
- Final height usually in lower half of target range



Males 3-18 years

# Intrauterine growth retardation (IUGR)

- **Asymmetric (HC>L>Wt)**  
3rd trimester malnutrition; catch-up growth during infancy; normal childhood growth and final height
- **Symmetric (HC=L=Wt)**  
prolonged intrauterine malnutrition; catch-up growth in infancy partial/absent; short stature in childhood despite normal growth rate; short adult

- Most infants born small for gestational age (SGA) experience catch-up growth by two years of age
- About 10 % of SGA infants, particularly those born with more severe SGA, do not experience catch-up growth to reach the normal range by two years of age.



# Dysmorphic syndromes

- Turner
- Noonan
- Silver Russel
- William
- Prader-Willi






# Skeletal dysplasia

- Frank skeletal abnormality affecting
  - epiphyses (epiphyseal dysplasia)
  - metaphyses (metaphyseal dysplasia)
  - spine (spondyleal dysplasia)

in various combinations (e.g. spondylo-epiphyseal dysplasia)

- Bone age tends to be advanced
- Adult height SDS < Childhood height SDS

## Stature divided into quarters



newborn

2

5

15

adult

Age (years)

# Achondroplasia



# Chronic systemic disease

Many different types

**Any** chronic condition (e.g. GI, cardiac, respiratory, renal, metabolic, CNS, joints) can cause short stature and/or slow growth

Chronic renal disease and GI disorders (e.g. coeliac disease) can be silent, and present with short stature.



# Social and emotional short stature

- Children from poor communities tend to be shorter than those from affluent areas
- Severe short stature with growth failure may result from emotional abuse/neglect (psychosocial deprivation)




# Endocrine disorders



- Growth hormone deficiency and resistance
- Thyroxine deficiency
- Cortisol excess
- Precocious puberty
- Idiopathic short stature

# Growth hormone

- anterior pituitary protein secreted by somatotrophs .
- antagonizes insulin action, promotes lipolysis in fat, and augments protein synthesis.
- Secretion is pulsatile
- Stimulated by sleep and exercise, inhibited by free fatty acids

## The Growth Hormone / IGF Axis





*L.J. Abernethy*

# Classification of growth hormone deficiency

- cause (congenital or acquired)
- nature (true permanent deficiency or functional/temporary insufficiency)
- severity (complete, severe or partial)
- whether isolated or part of multiple anterior pituitary deficiency

# Causes of hypopituitarism

## CONGENITAL

- Idiopathic
- Genetic defect
  - (i) isolated GH deficiency (AR, AD, X-linked)
  - (ii) multiple AP deficiency (eg PROP-1)
  - (iii) Prader-Willi synd
- Midline defects (e.g. septo-optic dysplasia)

## ACQUIRED

- Tumours (e.g. craniopharyngioma, optic glioma)
- Surgery
- Cranial radiotherapy (e.g. for medulloblastoma)
- Granulomatous disease (e.g. Langerhans cell histiocytosis)

# Idiopathic short stature

- Definitions vary according to different centres
- One definition is significant short stature ( $< -2.5$  SD) not attributable to normal familial short stature or constitutional delay or to other causes of short stature
- Heterogenous condition which may include partial GH resistance, mild skeletal dysplasias etc.

# Evaluation of the child with short stature - history

- History of growth pattern and previous measurements
- Parental heights, puberty
- Birthweight, postnatal hx
- General health
- Psychosocial situation



# Evaluation of the child with short stature - auxology

- Accurate measurement of child and parents
- Sibling measurement in selected cases
- Plot height and weight (nice dots!)
- Sitting height and leg length if disproportion suspected
- Plot mid parental height and target range
- Bone age by single observer

# Evaluation of the child with short stature - examination

- General appearance and nutrition
- Body proportions
- Dysmorphic features
- Systemic examination including heart
- BP
- Pubertal status
- Fundi

# Investigation of short stature

- Low threshold for karyotype in girls with short stature.
- Short stature screening
- Further short stature investigation

# Short stature screening

- FBC and film, ESR, TTG  
a'bodies,LFT,Blood gas
- Karyotype
- TFT, IGF-1,IGFBP3, prolactin, cortisol
- Creatinine, Lytes, calcium and phosphate
- Urinalysis and culture

# Further investigation of short stature

- Endocrine stimulation testing
  - ITT/arginine/clonidine/glucagon
- Pituitary imaging
- Genetic evaluation – clinical, laboratory
- Skeletal survey

## Low Incidence of Pathology Detection and High Cost of Screening in the Evaluation of Asymptomatic Short Children

Stephanie Sisley, MD<sup>1,\*</sup>, Marcela Vargas Trujillo, MD<sup>2,\*\*</sup>, Jane Khoury, PhD<sup>3</sup>, and Philippe Backeljauw, MD<sup>1</sup>

# Treatment

- Treat the cause.

# Conditions where growth hormone therapy is recommended

- Growth hormone deficiency
- Turner syndrome/Noonan Syndrome/SHOX
- Prader-Willi syndrome.
- SGA with no catch up by 4 years
- Chronic renal insufficiency.
- ISS ??



# Treatment of GH deficiency

## Recombinant human growth hormone (RHGH)

- Daily bedtime subcutaneous injections of aqueous solutions of biosynthetic (recombinant) GH
- Follow up q 3 months

norditropin®  
nordilet® 5mg/1.5 ml

mg	Dose	IU
0.07	1	0.21
0.13	2	0.39
0.20	3	0.60
0.27	4	0.81
0.33	5	0.99
0.40	6	1.20
0.47	7	1.41
0.53	8	1.59
0.60	9	1.80
0.67	10	2.01
0.73	11	2.19
0.80	12	2.40
0.87	13	2.61
0.93	14	2.79
1.00	15	3.00
1.07	16	3.21
1.13	17	3.39
1.20	18	3.60
1.27	19	3.81
1.33	20	3.99
1.40	21	4.20
1.47	22	4.41
1.53	23	4.59
1.60	24	4.80
1.67	25	5.01
1.73	26	5.19
1.80	27	5.40
1.87	28	5.61
1.93	29	5.79

norditropin®  
nordilet® 10mg/1.5 ml

mg	Dose	IU
0.13	1	0.39
0.27	2	0.81
0.40	3	1.20
0.53	4	1.59
0.67	5	2.01
0.80	6	2.40
0.90	7	2.79
1.07	8	3.21
1.20	9	3.60
1.33	10	3.99
1.47	11	4.41
1.60	12	4.80
1.73	13	5.19
1.87	14	5.61
2.00	15	6.00
2.13	16	6.31
2.27	17	6.81
2.40	18	7.20
2.53	19	7.59
2.67	20	8.01
2.80	21	8.40
2.93	22	8.79
3.07	23	9.21
3.20	24	9.60
3.33	25	9.99
3.47	26	10.41
3.60	27	10.80
3.73	28	11.19
3.87	29	11.61

norditropin®  
nordilet® 15mg/1.5 ml

mg	Dose	IU
0.20	1	0.60
0.40	2	1.20
0.60	3	1.80
0.80	4	2.40
1.00	5	3.00
1.20	6	3.60
1.40	7	4.20
1.60	8	4.80
1.80	9	5.40
2.00	10	6.00
2.20	11	6.60
2.40	12	7.20
2.60	13	7.80
2.80	14	8.40
3.00	15	9.00
3.20	16	9.60
3.40	17	10.20
3.60	18	10.80
3.80	19	11.40
4.00	20	12.00
4.20	21	12.60
4.40	22	13.20
4.60	23	13.80
4.80	24	14.40
5.00	25	15.00
5.20	26	15.60
5.40	27	16.20
5.60	28	16.80
5.80	29	17.40

**Clicks into mg**  
**Dose in mg**  
**Differs according to the indication of growth hormone treatment**



# Side Effects of GH Treatment

- Metabolic effects (hyperglycemia)
- Antibodies to growth hormone
- Progression of pre-existing scoliosis
- Slipped capital femoral epiphysis
- Pseudotumor cerebri
- Transient gynecomastia
- Increased growth and pigmentation of nevi
- Carpal tunnel syndrome
- Edema / Arthralgia
- Hypothyroidism
- Second neoplasms
  - Meningioma
- Pancreatitis

## Diagnostic Approach in Children with Short Stature

Wilma Oostdijk<sup>a</sup> Floor K. Grote<sup>a</sup> Sabine M.P.F. de Muinck Keizer-Schrama<sup>b</sup>  
Jan M. Wit<sup>a</sup>

<sup>a</sup>Department of Pediatrics, Leiden University Medical Center, Leiden, and <sup>b</sup>Department of Pediatrics, Erasmus MC – Sophia Children's Hospital, Rotterdam, The Netherlands



ELSEVIER

The Journal of Pediatrics

Volume 164, Issue 5, Supplement, May 2014, Pages S1-S14.e6

ELSEVIER

ELSEVIER



Supplement

# Etiologies and Early Diagnosis of Short Stature and Growth Failure in Children and Adolescents

Alan D. Rogol MD, PhD <sup>1</sup>  , Gregory F. Hayden MD <sup>2</sup>

Thank You